MedPath

Maraviroc

Generic Name
Maraviroc
Brand Names
Celsentri, Selzentry
Drug Type
Small Molecule
Chemical Formula
C29H41F2N5O
CAS Number
376348-65-1
Unique Ingredient Identifier
MD6P741W8A
Background

Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.

Indication

Maraviroc is indicated in combination with other antiretroviral agents for the treatment of CCR5-tropic HIV-1 infection in adults and pediatric patients weighing at least 2kg. It is not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1.

Associated Conditions
CCR5-tropic Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Related News

Investigating Measurable PRO Acuity Trial (IMPACT) is a Multi-Center Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Maraviroc and Atorvastatin to Improve Neurocognitive and Physical Function of Subjects With Long COVID-19/Post-Acute Sequelae of COVID-19 (PASC).

Phase 2
Not yet recruiting
Conditions
Long COVID
Interventions
Drug: Placebo, Maraviroc
Drug: Atorvastatin, 10mg, 20mg, 40mg
Drug: Placebo, Atorvastatin
First Posted Date
2025-05-15
Last Posted Date
2025-05-15
Lead Sponsor
HealthBio, Inc.
Target Recruit Count
252
Registration Number
NCT06974084
Locations
🇺🇸

University of Arizona, Tucson, Arizona, United States

This Study is Assessing the Safety and Efficacy of Immune Inhibition as a Treatment to Prevent Primary Graft Dysfunction

Phase 2
Not yet recruiting
Conditions
Primary Graft Dysfunction
Lung Transplantation
Acute Lung Injury(ALI)
Natural Killer Cell Mediated Immunity
Interventions
Drug: Placebo
First Posted Date
2025-02-28
Last Posted Date
2025-02-28
Lead Sponsor
University of California, San Francisco
Target Recruit Count
120
Registration Number
NCT06853223
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

Multi Interventional Approaches to Mitigate HIV Reservoirs Aiming the Sustained HIV Remission Without Antiretrovirals

Not Applicable
Not yet recruiting
Conditions
Hiv
HIV I Infection
Interventions
Drug: Sirtuin Histone deacetylase inhibitor
First Posted Date
2025-02-03
Last Posted Date
2025-02-03
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
70
Registration Number
NCT06805656
Locations
🇧🇷

CCDI, São Paulo, SP, Brazil

Antiviral Clinical Trial for Long Covid-19

Phase 2
Recruiting
Conditions
Long Covid
Interventions
Drug: Placebo
First Posted Date
2024-07-19
Last Posted Date
2024-12-20
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
90
Registration Number
NCT06511063
Locations
🇺🇸

The Cohen Center for Recovery from Complex Chronic Illnesses (CoRE), New York, New York, United States

Safety of Maraviroc for Post-stroke Depression

Phase 2
Completed
Conditions
Post-stroke Depression
Interventions
First Posted Date
2023-07-06
Last Posted Date
2023-07-06
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
10
Registration Number
NCT05932550
Locations
🇮🇱

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

Phase 1
Recruiting
Conditions
HIV
Hematologic Malignancies
Interventions
Drug: GVHD prophylaxis
Procedure: allo HCT
First Posted Date
2022-07-22
Last Posted Date
2025-05-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
265
Registration Number
NCT05470491
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Safety and Efficacy of Maraviroc in Post-stroke Cognitive Impairment

Phase 2
Conditions
Post Stroke Cognitive Impairment
Interventions
First Posted Date
2021-07-19
Last Posted Date
2021-07-19
Lead Sponsor
Tel-Aviv Sourasky Medical Center
Target Recruit Count
150
Registration Number
NCT04966429
Locations
🇮🇱

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

The Role of Home Packs of HIV PEPSE in High Risk Individuals

Phase 4
Completed
Conditions
HIV-1-infection
Interventions
First Posted Date
2021-07-16
Last Posted Date
2021-07-22
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Target Recruit Count
139
Registration Number
NCT04965662
Locations
🇬🇧

Guy's & St. Thomas' NHS Foundation Trust, London, Greater London, United Kingdom

The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke

Phase 2
Recruiting
Conditions
Stroke
Interventions
Behavioral: Exercise Program
Other: Placebo
Device: Activity Sensor
Behavioral: Motor Learning
First Posted Date
2021-03-09
Last Posted Date
2024-07-09
Lead Sponsor
University of Calgary
Target Recruit Count
120
Registration Number
NCT04789616
Locations
🇨🇦

Dalhousie University, Halifax, Nova Scotia, Canada

🇨🇦

Toronto Rehabilitation Institute - University Health Network, Toronto, Ontario, Canada

🇨🇦

Parkwood Institute, London, Ontario, Canada

and more 3 locations

Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)

Phase 2
Completed
Conditions
Virus Diseases
Interventions
Other: Standard treatment
First Posted Date
2021-01-14
Last Posted Date
2023-05-06
Lead Sponsor
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Target Recruit Count
44
Registration Number
NCT04710199
Locations
🇪🇸

Hospital Universitario Virgen del Rocio, Sevilla, Spain

🇪🇸

Hospital Universitario Virgen del Rocío, Sevilla, Spain

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy